Financial Analysis: Quanterix (NASDAQ:QTRX) & Danaher (NYSE:DHR)

Quanterix (NASDAQ:QTRX – Get Free Report) and Danaher (NYSE:DHR – Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk and earnings.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Quanterix and Danaher, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Quanterix 1 2 0 0 1.67
Danaher 0 5 18 0 2.78

Quanterix presently has a consensus target price of $3.50, suggesting a potential upside of 23.24%. Danaher has a consensus target price of $242.91, suggesting a potential upside of 5.61%. Given Quanterix’s higher probable upside, equities research analysts clearly believe Quanterix is more favorable than Danaher.

Valuation and Earnings

This table compares Quanterix and Danaher”s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Quanterix $138.90 million 0.97 -$107.15 million ($2.36) -1.20
Danaher $24.57 billion 6.59 $3.61 billion $6.11 37.64

Danaher has higher revenue and earnings than Quanterix. Quanterix is trading at a lower price-to-earnings ratio than Danaher, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

86.5% of Quanterix shares are held by institutional investors. Comparatively, 79.0% of Danaher shares are held by institutional investors. 1.5% of Quanterix shares are held by insiders. Comparatively, 10.8% of Danaher shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Quanterix and Danaher’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Quanterix -75.05% -30.49% -22.44%
Danaher 16.91% 11.17% 6.71%

Volatility and Risk

Quanterix has a beta of 1.06, indicating that its share price is 6% more volatile than the S&P 500. Comparatively, Danaher has a beta of 0.76, indicating that its share price is 24% less volatile than the S&P 500.

Summary

Danaher beats Quanterix on 10 of the 13 factors compared between the two stocks.

About Quanterix

(Get Free Report)

Quanterix Corporation develops technologies for measuring biomarkers in biological samples. Its Simoa (Single Molecule Array) platform is designed to detect proteins and other biomarkers at very low concentrations, supporting research in areas such as neurology, oncology, immunology and cardiovascular disease. The company provides laboratory instruments, assay kits, consumables and related services. Its products are used by pharmaceutical and biotechnology companies, academic institutions and laboratories to study disease biology and evaluate potential biomarkers in samples such as blood and cerebrospinal fluid.

About Danaher

(Get Free Report)

Danaher is a global science and technology company that develops and supplies products and services for biotechnology, life sciences, and diagnostics markets. Its offerings include instruments, reagents, consumables, software, and services used in research, drug development and manufacturing, and clinical testing. The company’s businesses include well-known brands such as Cytiva and Pall in bioprocessing and filtration, Beckman Coulter in laboratory and clinical diagnostics, Cepheid in molecular diagnostics, and Leica Microsystems in microscopy.

Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.